使用恩格列净治疗 2 型糖尿病患者的代谢控制:病例系列。

IF 1.2 Q2 MEDICINE, GENERAL & INTERNAL
Wilfredo Navarrete, Pilar Durruty, Eileen Andrade, Rodrigo Orellana, María Georgina Ortiz, María Angélica Budini
{"title":"使用恩格列净治疗 2 型糖尿病患者的代谢控制:病例系列。","authors":"Wilfredo Navarrete, Pilar Durruty, Eileen Andrade, Rodrigo Orellana, María Georgina Ortiz, María Angélica Budini","doi":"10.5867/medwave.2024.03.2758","DOIUrl":null,"url":null,"abstract":"Background\nType 2 diabetes mellitus is a highly prevalent disease and is associated with increased morbidity and mortality. Due to the low percentage of adequate glycemic control, new strategies for the treatment of type 2 diabetes mellitus have been sought, including sodium-glucose cotransporter type 2 inhibitorss.\n\n\nObjective\nTo describe the evolution of patients with type 2 diabetes mellitus with insulin requirements treated with empagliflozin at the Peñaflor Hospital. The primary objective was to evaluate the efficacy of the medication regarding glycosylated hemoglobin A1c (HbA1c). The secondary objectives were: 1) achievement of HbA1c equal to or less than 7.5% according to survival analysis. 2) Change in glomerular filtration rate and urinary albumin excretion post treatment.\n\n\nMethods\nReview of clinical records of all patients treated with empagliflozin from November 2019 to June 2023. Average follow-up of 19 (16.3 to 40) months. To compare HbA1c values according to follow-up ranges, the paired T test or Wilcoxon test was used.\n\n\nResults\nWe included 58 patients, 15 men and 43 women (74.1%), with an average age of 58.5 ± 9.2 years, ranging from 35 to 75 years. Baseline HbA1c of 10.3 ± 1.6% and 8.98% ± 2.2 in a follow-up of 18 to 24 months post-treatment, resulted in a decrease of 1.27% (p = 0.002; confidence interval 95%: 0.5 to 2.03). The most common adverse effect was urinary tract infection.\n\n\nConclusions\nPatients with type 2 diabetes mellitus with insulin requirements treated with empagliflozin at the Peñaflor Hospital achieved better glycemic control with few adverse effects.","PeriodicalId":18597,"journal":{"name":"Medwave","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metabolic control in type 2 diabetic patients treated with empagliflozin: A case series.\",\"authors\":\"Wilfredo Navarrete, Pilar Durruty, Eileen Andrade, Rodrigo Orellana, María Georgina Ortiz, María Angélica Budini\",\"doi\":\"10.5867/medwave.2024.03.2758\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background\\nType 2 diabetes mellitus is a highly prevalent disease and is associated with increased morbidity and mortality. Due to the low percentage of adequate glycemic control, new strategies for the treatment of type 2 diabetes mellitus have been sought, including sodium-glucose cotransporter type 2 inhibitorss.\\n\\n\\nObjective\\nTo describe the evolution of patients with type 2 diabetes mellitus with insulin requirements treated with empagliflozin at the Peñaflor Hospital. The primary objective was to evaluate the efficacy of the medication regarding glycosylated hemoglobin A1c (HbA1c). The secondary objectives were: 1) achievement of HbA1c equal to or less than 7.5% according to survival analysis. 2) Change in glomerular filtration rate and urinary albumin excretion post treatment.\\n\\n\\nMethods\\nReview of clinical records of all patients treated with empagliflozin from November 2019 to June 2023. Average follow-up of 19 (16.3 to 40) months. To compare HbA1c values according to follow-up ranges, the paired T test or Wilcoxon test was used.\\n\\n\\nResults\\nWe included 58 patients, 15 men and 43 women (74.1%), with an average age of 58.5 ± 9.2 years, ranging from 35 to 75 years. Baseline HbA1c of 10.3 ± 1.6% and 8.98% ± 2.2 in a follow-up of 18 to 24 months post-treatment, resulted in a decrease of 1.27% (p = 0.002; confidence interval 95%: 0.5 to 2.03). The most common adverse effect was urinary tract infection.\\n\\n\\nConclusions\\nPatients with type 2 diabetes mellitus with insulin requirements treated with empagliflozin at the Peñaflor Hospital achieved better glycemic control with few adverse effects.\",\"PeriodicalId\":18597,\"journal\":{\"name\":\"Medwave\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-04-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medwave\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5867/medwave.2024.03.2758\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medwave","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5867/medwave.2024.03.2758","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景2型糖尿病是一种高发疾病,与发病率和死亡率的增加有关。由于充分控制血糖的比例较低,人们一直在寻找治疗2型糖尿病的新策略,包括钠-葡萄糖共转运体2型抑制剂。目的描述培尼亚弗洛医院使用empagliflozin治疗有胰岛素需求的2型糖尿病患者的演变情况。首要目标是评估药物对糖化血红蛋白 A1c (HbA1c) 的疗效。次要目标是1) 根据生存分析,HbA1c 达到或低于 7.5%。2)治疗后肾小球滤过率和尿白蛋白排泄量的变化。方法回顾2019年11月至2023年6月所有接受empagliflozin治疗的患者的临床记录。平均随访 19(16.3 至 40)个月。根据随访范围比较HbA1c值,采用配对T检验或Wilcoxon检验。结果我们纳入了58名患者,其中男性15名,女性43名(74.1%),平均年龄为(58.5±9.2)岁,从35岁到75岁不等。基线 HbA1c 为 10.3 ± 1.6%,在治疗后 18 至 24 个月的随访中为 8.98% ± 2.2,降低了 1.27%(p = 0.002;置信区间 95%:0.5 至 2.03)。最常见的不良反应是尿路感染。结论在培尼亚弗洛医院接受empagliflozin治疗的有胰岛素需求的2型糖尿病患者的血糖控制较好,不良反应较少。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Metabolic control in type 2 diabetic patients treated with empagliflozin: A case series.
Background Type 2 diabetes mellitus is a highly prevalent disease and is associated with increased morbidity and mortality. Due to the low percentage of adequate glycemic control, new strategies for the treatment of type 2 diabetes mellitus have been sought, including sodium-glucose cotransporter type 2 inhibitorss. Objective To describe the evolution of patients with type 2 diabetes mellitus with insulin requirements treated with empagliflozin at the Peñaflor Hospital. The primary objective was to evaluate the efficacy of the medication regarding glycosylated hemoglobin A1c (HbA1c). The secondary objectives were: 1) achievement of HbA1c equal to or less than 7.5% according to survival analysis. 2) Change in glomerular filtration rate and urinary albumin excretion post treatment. Methods Review of clinical records of all patients treated with empagliflozin from November 2019 to June 2023. Average follow-up of 19 (16.3 to 40) months. To compare HbA1c values according to follow-up ranges, the paired T test or Wilcoxon test was used. Results We included 58 patients, 15 men and 43 women (74.1%), with an average age of 58.5 ± 9.2 years, ranging from 35 to 75 years. Baseline HbA1c of 10.3 ± 1.6% and 8.98% ± 2.2 in a follow-up of 18 to 24 months post-treatment, resulted in a decrease of 1.27% (p = 0.002; confidence interval 95%: 0.5 to 2.03). The most common adverse effect was urinary tract infection. Conclusions Patients with type 2 diabetes mellitus with insulin requirements treated with empagliflozin at the Peñaflor Hospital achieved better glycemic control with few adverse effects.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medwave
Medwave MEDICINE, GENERAL & INTERNAL-
CiteScore
2.60
自引率
8.30%
发文量
50
审稿时长
12 weeks
期刊介绍: Medwave is a peer-reviewed, biomedical and public health journal. Since its foundation in 2001 (Volume 1) it has always been an online only, open access publication that does not charge subscription or reader fees. Since January 2011 (Volume 11, Number 1), all articles are peer-reviewed. Without losing sight of the importance of evidence-based approach and methodological soundness, the journal accepts for publication articles that focus on providing updates for clinical practice, review and analysis articles on topics such as ethics, public health and health policy; clinical, social and economic health determinants; clinical and health research findings from all of the major disciplines of medicine, medical science and public health. The journal does not publish basic science manuscripts or experiments conducted on animals. Until March 2013, Medwave was publishing 11-12 numbers a year. Each issue would be posted on the homepage on day 1 of each month, except for Chile’s summer holiday when the issue would cover two months. Starting from April 2013, Medwave adopted the continuous mode of publication, which means that the copyedited accepted articles are posted on the journal’s homepage as they are ready. They are then collated in the respective issue and included in the Past Issues section.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信